Answers are grounded in this paper and cite their sources.
This work was undertaken to study the distribution of VIP in the digestive tract. VIP was measured both by radioimmunoassay and by radioreceptorassay in order to determine whether immunoreactive VIP is related to a biologically active component. The effect of digestive extracts in inhibiting the binding of porcine [125I]VIP to the antibody (RIA) and to the rat liver plasma membranes (RRA) paralleled that of porcine VIP used as the standard. VIP was found throughout the digestive tract with especially high concentrations between the duodenum (1676 ± 186 ng/g) and the colon (1214 ± 214 ng/g); the maximal quantity occurred in the jejuno-ileum (11 698 ± 687 ng/g). Less than 1 % of VIP was found in the epithelium whereas almost all VIP (> 99%) was localized in the mucosal muscular tissue of the jejunoileum. VIP concentration in the pancreas was 180 ± 26 ng/g of tissue. The VIP contents of the digestive tract were similar when measured either by radioimmunoassay or by radioreceptorassay. Immunoreactive VIP was found in the brain (155 ± 7 ng/g of tissue) and brain extracts competitively inhibited the binding of [125I]VIP (purified from gut) to liver plasma membranes. These results show that: 1) VIP from the overall gastrointestinal tract is a biological active molecule: 2) VIP from brain binds to receptors for intestinal VIP in liver.
No takes yet. Share an insight, caveat, or question.
Besson et al. (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: